GLP-1 Analogs and Trabecular Meshwork Function
The trabecular meshwork (TM) is a vital ocular structure that regulates intraocular pressure (IOP), and its dysfunction is a significant risk factor for the development of glaucoma. Recent studies have highlighted the importance of the TM in maintaining normal eye function and have shed light on potential therapeutic targets for glaucoma treatment. In this article, we will discuss the recent advances in our understanding of the TM function and explore the potential benefits of GLP-1 analogs in preserving TM function.The Physiology of the Trabecular Meshwork
The TM is a complex, three-dimensional structure composed of trabecular meshwork cells (TMC) interdigitated with extracellular matrix (ECM). This intricate structure is responsible for the drainage of aqueous humor from the eye, and dysfunction of the TM is a leading cause of glaucoma. The TMC have inherent contractility and can regulate aqueous outflow by modulating their connections with and altering the properties of their surrounding ECM.The Role of GLP-1 in Trabecular Meshwork Function
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that plays a crucial role in glucose homeostasis. Recent studies have demonstrated that GLP-1 also has a significant impact on TM function. The interaction between GLP-1 and its receptor (GLP-1R) in the TM has been found to modulate TM contractility, fluid outflow, and IOP. GLP-1 exerts its effects by increasing cAMP levels via adenylyl cyclase activation, which triggers a cascade of downstream effects that promote insulin release, improved glycemic control, and enhanced TM function.The Benefits of GLP-1 Analogs on Trabecular Meshwork Function
